This site is intended for healthcare professionals

Speciality hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 30th Mar 2020

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

Learning Zone Homepage

COMT inhibition in Parkinson’s Disease

The COMT inhibition in Parkinson's Disease Learning Zone contains key information, expert opinion and interactive learning to highlight the benefit to patients of early levodopa treatment and diagnosis of the motor fluctuations which signal disease progression and prompt adjunctive treatment. Also detailing key efficacy and safety data for the approved COMT inhibitors to help inform your treatment decisions.

Learning Zone Homepage

Spinal Muscular Atrophy

SMA is caused by loss of function mutations or deletions in the SMN1 gene, which results in insufficient levels of the survival of motor neuron (SMN) protein. Find out more here.

Learning Zone Homepage

Neuroscience and Pain Learning Zone

A focus on ADHD, Alzheimer's disease, epilepsy and pain. Videos within each section, world-leading experts will help you diagnose these often challenging conditions.

Latest news and insights

Retrospective study of Velphoro in Hyperphosphataemia published in Kidney Medicine journal.- Fresenius Medical

A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro (sucroferric oxyhydroxide chewable tablets), from Fresenius Medical, achieved target serum phosphorous levels of less than or equal to 5.5 mg/dL compared to those patients who

1 mins

CHMP recommends extension of approval for Adcetris plus CHP in anaplastic large cell lymphoma.- Takeda Pharma

Takeda Pharmaceutical Co announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with CHP (cyclophosphamide,

1 min

Phase III study of Saxenda in adolescent obesity published in New England Journal of Medicine.- Novo Nordisk

Novo Nordisk announced that the New England Journal of Medicine published results of a phase III trial evaluating the investigational use of Saxenda (liraglutide) injection 3.0 mg in adolescents (aged 12– 18) with obesity.

1 min

See all news

Latest Clinical Guidelines, Trials and Journals

Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study

This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics...

2 mins

Repair of large and giant incisional hernia with onlay mesh: Perspective of a tertiary care hospital of a developing country

Purpose: Ventral incisional hernias, especially large and giant, carry significant post repair complications. This retrospective review is undertaken to determine...

1 min

UK guidelines on the management of variceal haemorrhage in cirrhotic patients

These updated guidelines on the management of variceal haemorrhage have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG.

1 min

Your peers are looking at...

rivaroxaban significantly reduced risk of major venous thromboembolism following non major orthopaedic surgery.

rivaroxaban significantly reduced risk of major venous thromboembolism following non major orthopaedic surgery.

2 mins

Rivaroxaban significantly reduced risk of major venous thromboembolism following non-major orthopaedic surgery. Bayer Healthcare + Janssen Pharma

Rivaroxaban significantly reduced risk of major venous thromboembolism following non-major orthopaedic surgery. Bayer Healthcare + Janssen Pharma

2 mins

Rivaroxaban significantly reduced risk of major venous thromboembolism following non-major orthopaedic surgery. Bayer Healthcare + Janssen Pharma

Rivaroxaban significantly reduced risk of major venous thromboembolism following non-major orthopaedic surgery. Bayer Healthcare + Janssen Pharma

2 mins

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

1 mins

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

1 mins

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

1 mins

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

1 mins

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

1 mins

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

1 mins

Latest Events & Event Resources

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2020

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2020

Alzheimer's Association International Conference (AAIC) 2020

Alzheimer's Association International Conference (AAIC) 2020

European Academy of Neurology (EAN) 2020

European Academy of Neurology (EAN) 2020